Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of serum markers containing alpha fetal protein (AFP), Golgi protein 73 (GP73) and carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM1) in diagnosis of liver diseases

A technology for liver diseases and uses, which is applied in the field of kits for diagnosing liver cancer, and can solve problems such as false negatives

Inactive Publication Date: 2017-11-14
THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when the three indicators are used alone, there are certain false negatives and false positives. If the three indicators are jointly detected in an appropriate way and means, and complement each other, it will help to further reduce the risk of clinical diagnosis of hepatocellular carcinoma. False Negatives and False Positives

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of serum markers containing alpha fetal protein (AFP), Golgi protein 73 (GP73) and carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM1) in diagnosis of liver diseases
  • Use of serum markers containing alpha fetal protein (AFP), Golgi protein 73 (GP73) and carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM1) in diagnosis of liver diseases
  • Use of serum markers containing alpha fetal protein (AFP), Golgi protein 73 (GP73) and carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM1) in diagnosis of liver diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0027] The reagents used in the present invention were purchased from ORIGENE, ROCKVILLE, MD, USA.

[0028] The samples used in the experiment came from the Laboratory Department of Peking Union Medical College Hospital, the Department of Digestive Oncology of 307 Hospital, and Zhongshan Cancer Hospital. Serum samples were obtained through the relevant ethics review committee (Hospital / Medical Academy Basic Institute) with informed exemption. For healthy samples, those with normal liver biochemical test values, no history of liver disease, no history of alcoholism, and no other solid tumors; for HBV cases, HBSAG (+) is required under the premise of the above requirements; liver cirrhosis cases are those with liver biopsy or Clinical, laboratory, imaging diagnosis; primary HCC was confirmed by histopathology or two different imaging (ultrasound, computed tomography, magnetic resonance imaging, angiography) showing arterial enhancing lesions. The sample was taken from the antec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to use of serum markers containing alpha fetal protein (AFP), Golgi protein 73 (GP73) and carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM1) in diagnosis of liver diseases. Specifically, the invention provides use of reagents containing an associative part of at least one specific binding AFP, an associative part of at least one specific binding GP73 and an associative part of at least one specific binding CECAM1 protein in preparation of kits for diagnosis and / or prognosis of the liver diseases.

Description

technical field [0001] The present invention relates to the use of AFP (alpha-fetoprotein), GP73 (Golgi protein 73) and CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1) as markers for the diagnosis of liver diseases. Specifically, the present invention relates to the use of an antibody specifically binding to AFP, GP73 and CEACAM1 in the preparation of a kit for diagnosing liver cancer. Background technique [0002] According to WHO data in 2008, the incidence of liver cancer ranks fifth among all tumors, and its death rate ranks third. It ranks fifth and seventh among common cancers in men and women, respectively. The number of cases is 695,900, and there is an increasing trend year by year. As the main type of liver cancer, hepatocellular carcinoma (HCC) accounts for about 70% to 85% of the whole, see Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cance...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68G01N33/574G01N33/576
CPCG01N33/57438G01N33/57473G01N33/57484G01N33/576G01N33/68
Inventor 程根宏秦晓峰幸雯张涛隋天琪鲁宁
Owner THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com